CYP19A1 and cancer: Reduction in blood oestrogen from inhibition of aromatase with reduction of oestrogen-dependent cancer cell growth and clinical response25 has clear mechanistic parallels to the reduction in peripheral blood arginine and inhibition of CNS cancer growth achieved by ADI-PEG20.